Frederic Pette’s Post

Exciting Milestone for BioMAdvanced Diagnostics! We're thrilled to unveil the commercial name for our project formerly known as "SRDK0921" ✨BioMAdvanced Kidney SCR Score 🚀Along with its new name, we're also introducing its dedicated logo, aligning closely with our established corporate identity now protected and registered across the EU, USA, and Japan.   Why this name ? ✔We will have other applications following this one, it was therefore mandatory to precise both the target organ and condition in the name.   ✔The "SCR" in the name stands for Sub-Clinical Rejection, pinpointing the test's unique focus and specialization. 🧪BioMAdvanced Kidney SCR Score is one of the few tests completely specific and dedicated to detecting early the absence of SCR of a kidney transplant, providing specific insights that are critical for early intervention and a true personalized medicine approach. 📅As we move into the final clinical phase with results anticipated by year-end, our focus shifts towards achieving a CE mark by end of 2025. Next on our launch roadmap, we are now actively seeking a commercial partner to prepare for a successful European market launch. #Atlanpole #AtlanpoleBiotherapies #LaFrenchCare #medtech #KidneyHealth

Prof. Fredric O. Finkelstein, M.D., is joining Byonyks as a scientific advisor. Before joining the company, he wrote the following article. I'm excited to share that it validates the important work we are doing at Byonyks to revolutionize peritoneal dialysis (PD). The article published in Kidney International Reports highlights the critical need for innovations in PD to reduce inflammation, preserve the peritoneal membrane, and improve patient comfort and outcomes. As the article states, "Innovations in PD are needed to improve patient outcomes and quality of life." This is precisely the mission we are pursuing at Byonyks - to develop next-generation PD devices that are biocompatible, toxin-free, and help preserve peritoneal membrane integrity. Our solutions aim to deliver higher-quality treatments more efficiently, allowing patients to maintain an active lifestyle. We are excited to bring real innovation to the PD space and partner with the nephrology community to elevate patient care. Stay tuned for more updates as we work to commercialize our solutions in the US market. Link: https://lnkd.in/gWSAbUj8

Later this month, our CEO, Thomas Holm Pedersen, and SVP, Corporate and Commercial Strategy, Dan Brennan, will be in London for this year’s Jefferies Global Healthcare Conference. Held from 19-21 November, this year’s gathering marks the 15th anniversary of Europe’s largest healthcare-dedicated conference, and we look forward to joining other leading #biotech and pharma executives, #investors and potential partners to discuss NMD Pharma’s corporate strategy and recent progress developing novel treatments to improve muscle function and quality of life of patients with neuromuscular diseases. If you will also be on the ground in London and would like to hear more about our novel skeletal muscle-specific chloride 1 ion channel (ClC-1) inhibitor approach, which has the potential to improve muscle power and endurance in patients living with severe neuromuscular disorders, please contact contact@nmdpharma.com to set up a meeting. #JefferiesHealthcare #InvestorConference #Innovation #NeuromuscularDisease #NMDPharma

Today is #GlobalDayAgainstPain. Rapport is proud to be working toward the next frontier in pain medicine to one day give patients a better quality of life, with two different pain programs currently in development.   Our first pain program centers on peripheral neuropathic pain, a chronic condition caused by damaged or dysfunctional peripheral nerves, affecting millions of people worldwide. We’ll be evaluating our lead small molecule candidate RAP-219 in patients with this condition in an upcoming Phase 2a study. Our discovery stage pain program is more broadly focused on chronic pain indications, which may include neuropathic pain, inflammatory pain and more.    Bradley Galer, Chief Medical Officer, offers thoughts below on the enormous unmet need that exists for those living with pain conditions as well as Rapport’s mission to improve patient lives and change health outcomes through the development of novel therapeutics.   You can find more information on how Rapport is addressing pain on our website: https://bit.ly/3A5KFJp   #PainManagement #Biotech

1️⃣ Boston Scientific’s cardiac rhythm system hits pivotal trial goals. Boston Scientific, which presented the results at the Heart Rhythm Society meeting, expects to receive FDA approval for the system in 2025. 2️⃣ KT has introduced two new patches for diabetes care, featuring Pro Extreme adhesive to prevent CGM device detachment. 3️⃣ Click Therapeutics, Inc. has acquired assets from Better Therapeutics, potentially enhancing its portfolio in obesity, diabetes, and cardiometabolic diseases. 4️⃣ Indica Labs received FDA 510(k) clearance for its HALO AP Dx platform, which diagnoses surgical pathology slides. 5️⃣ Irmed’s PressureSafe device has shown to reduce pressure injury incidence by half in early detections. 6️⃣ Invizius completed a Phase I trial of its dialysis priming product, H-Guard, confirming its safety and efficacy. 7️⃣ Allez Health raised $60m led by Osang Healthcare to enhance its diabetes sensor technology. 8️⃣ MEDLINE INDUSTRIES LIMITED, LP introduced the TurboMist small-volume nebuliser, delivering medication more efficiently than standard nebulisers. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

🚨 In the News 🚨 We’re excited to see Imbed Biosciences featured for their groundbreaking achievement! On October 31st, the FDA approved Microlyte Ag/Lidocaine, the first-ever antimicrobial wound dressing that combines lidocaine with silver for antimicrobial control. This innovative dressing brings dual benefits: providing antimicrobial protection and local anesthetic effects, ideal for managing painful wounds. Read the full mention on this in the article below, as Imbed Biosciences continues to lead the way in advanced wound care. 📖 #InTheNews #HealthcareInnovation #WoundCare #FDAApproval #PainManagement #ImbedBiosciences #MedicalBreakthrough

🌟 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸'𝘀 𝗛𝗲𝗺𝗹𝗶𝗯𝗿𝗮 𝗥𝗶𝘃𝗮𝗹 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗦𝘂𝗰𝗰𝗲𝘀𝘀, 𝗦𝗲𝘁𝘁𝗶𝗻𝗴 𝗦𝘁𝗮𝗴𝗲 𝗳𝗼𝗿 𝗕𝗹𝗼𝗰𝗸𝗯𝘂𝘀𝘁𝗲𝗿 𝗦𝗵𝗼𝘄𝗱𝗼𝘄𝗻 𝘄𝗶𝘁𝗵 𝗥𝗼𝗰𝗵𝗲💊 𝗜𝗻 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟰, Novo Nordisk is vying for Hemlibra from Roche. The Danish drugmaker's rival to the popular #hemophilia medicine reached its key endpoint in a phase 3 trial, paving the way for an application📃 for approval sometime before the end of the year.By using Mim8, a 💉bispecific #antibody that bridges Factor IXa and X to replace absent Factor VIII, Novo Nordisk is controlling bleeding in a manner similar to that of Roche's Hemlibra. According to Novo Nordisk, the #treatment💊 was well tolerated and safe; there were no recorded thromboembolic events or deaths during the trial. One area Novo Nordisk thought it might have an advantage is efficacy. More than 70% of individuals may no longer require treatment for bleeding while using Mim8. 𝗟𝗼𝗼𝗸 𝗮𝘁 𝗼𝘂𝗿 𝗖𝗼𝗿𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3UPaDID #NovoNordisk #Roche #Haemophilia #Phase3Trials #ClinicalTrials #Hemlibra #prophecymarketinsights

WAVE trial six-month data show “tremendous” results for WRAPSODY The six-month results of the WAVE (WRAPSODY Arteriovenous Access Efficacy) pivotal trial have reported superior target lesion primary patency (TLPP) with the WRAPSODY (Merit Medical) cell-impermeable endoprosthesis when compared to percutaneous transluminal angioplasty (PTA) when used in failing arteriovenous fistulas (AVF). Experts note that based on these results, covered stents could potentially be a first-line treatment in dedicated lesion sites, ushering in an era of tailored therapy for dialysis patients.   Read more: https://lnkd.in/eFQgmxdj #InnovatingHealthcare This video, intended for our audience in countries where WRAPSODY is CE marked, is sponsored by Merit Medical Systems, Inc.

In a systematic review of 88 studies, 13% of locally advanced/metastatic urothelial #carcinoma cases were HER2+, and an additional 17.5% were HER2-low. Explore new frontiers in the management of UC in this free, case-based #CME activity: https://bit.ly/41wIKZw #MedEd #FOAMed

Our latest research from Dr. Rehan's group introduces a groundbreaking approach to treat ulcerative colitis (UC). We’ve developed site-specific thiolated mucoadhesive anionic nanoliposomes that address the limitations of conventional enema therapy. This innovative delivery system, loaded with Gallic Acid (GA), offers targeted adhesion to inflamed colon sites, promoting prolonged drug residence and superior therapeutic efficacy. Our studies show that GATh@APDL effectively mitigates colonic inflammation, downregulates proinflammatory expressions, and enhances mucosal healing. 🌟 These findings represent a significant step forward in UC treatment, offering new hope for patients by overcoming the challenges of traditional therapies. We're excited about the potential of GATh@APDL in revolutionizing the management of UC. 🔗 https://lnkd.in/dwf6tbtV. Kindly share this article First ones are always special ones Special thanks to my supervisor @Rehan Khan for consistent support and suggestions and congratulations to all co-authors Ajay Kumar (Affiliate) MRSC @Anas Ahmad #UlcerativeColitis #Nanotechnology #DrugDelivery #MucosalHealing #InnovativeResearch #TeamScience